Oruka Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
The company is advancing best-in-class IL-23 and IL-17A/F therapies for psoriatic disease, with phase II data showing high efficacy and flexible dosing options. Key upcoming milestones include additional EVERLAST-A data, phase III readiness, and expansion into new indications, all supported by strong financials.
-
The meeting confirmed a quorum and addressed three proposals: director elections, auditor ratification, and executive compensation. All proposals passed, with final vote totals to be filed with the SEC.
-
Interim phase II data for ORKA-001 in moderate-to-severe psoriasis show 63.5% PASI 100 at week 16, surpassing other IL-23 inhibitors and matching top IL-17A/F agents. Safety is favorable, and PK supports annual dosing. A 28-week update and pivotal trial planning are upcoming.
-
Ultra-long acting antibodies targeting IL-23p19 and IL-17AF aim to transform psoriatic disease care with annual or semi-annual dosing, high efficacy, and potential off-treatment remission. Key Phase II data for ORKA-001 is expected in the second half of the year.
-
The company is advancing two long-acting monoclonal antibodies for psoriatic disease, aiming for annual or biannual dosing and potential off-treatment remission. Key phase II data are expected in 2024–2025, with a strong financial position and innovative trial designs supporting differentiation from current standards.
Fiscal Year 2025
-
Two lead monoclonal antibody programs are advancing in psoriatic disease, targeting once or twice-yearly dosing and aiming for high efficacy and durable remission. Key phase II and I data readouts are expected through 2027, supported by a strong cash position.
-
Oruka is advancing biologics for psoriatic disease with ultra-long dosing intervals and aims for multi-year remission, leveraging strong clinical design and a robust cash position. Sequential and combination regimens with ORKA-001 and ORKA-002 target best-in-class efficacy and safety.